Background. Skeletal muscle depletion, referred to as sarcopenia, predicts mortality in patients
previous studies investigated only skeletal muscle mass to define sarcopenia, because muscle strength and function are difficult to evaluate. To the best of our knowledge, no reports regarding the relationship between quality of skeletal muscle and prognosis of pancreatic cancer patients following curative pancreatic resection have been presented.
Recently, increased intramuscular adipose tissue with aging has been identified as a potential contributor to declined muscle strength and quality. Loss of muscle strength is known to depend on both a decrease in muscle mass and accumulation of intramuscular adipose tissue. 11 To determine the quality of skeletal muscle, Kitajima et al. evaluated skeletal muscle steatosis by measuring intramuscular adipose tissue content (IMAC) using computed tomography (CT), and found that skeletal muscle steatosis was linked to the pathogenesis and severity of non-alcoholic steatohepatitis. 12, 13 Thus, skeletal muscle quality has recently attracted much attention, though the impact on surgical patients remains unknown.
In the present study, we evaluated quality as well as quantity of skeletal muscle by determining IMAC and psoas muscle mass index (PMI), respectively, using preoperative plain CT imaging. We also investigated the impact of PMI and IMAC as indicators of overall quantity and quality of skeletal muscle on outcome in patients undergoing resection of pancreatic cancer.
Methods

Patients and data collection
We investigated 230 patients who underwent resection for pancreatic cancer with curative intent between January 2004 and June 2013 at Kyoto University. Clinical and pathological data were collected, including tumor characteristics and postoperative overall survival (OS) and recurrence-free survival (RFS) rates. There were 124 men (53.9 %) and 106 women (46.1%), and their median age was 67 years (range 32-87 years). Median tumor size was 2.8 cm (0.5-7.5 cm). Pathologocal diagnosis of all patients was pancreatic ductal adenocarcinoma. Pathological stages according to Union for International Cancer Control (UICC) staging were Ia, Ib, IIa, IIb, III, and IV in 5 (2.1%), 8 (3.5%), 77 (33.5%), 129 (56.1%), 3 (1.3%) and 8 (3.5%) patients, respectively. Lymph node metastasis was identified in 135 patients (58.7%). We used 3 different types of surgical procedures; pancreaticoduodenectomy (PD) (including classic Whipple procedure, pylorus preserving pancreaticoduodenectomy, subtotal stomach preserving pancreaticoduodenectomy) (n = 155), distal pancreatectomy (DP) (n = 66), and total pancreatectomy (n = 7). Our current indication for resection is UICC stage Ia/Ib/IIa/IIb. Though there are some patients with UICC stage III/IV in this analysis, they were exceptional cases in the early period of the study, and they are not our surgical indication now. After discharge, all patients were examined for recurrence by determining tumor markers every 3 months, and by CT or magnetic resonance imaging every 6 months during the follow-up course.
Image analysis
Using preoperative plain CT at the umbilical level, the cross-sectional areas of the bilateral psoas muscles were measured by manual tracing, then PMI was calculated as follows. Low PMI was regarded as a proxy for low muscle volume ( Fig 1A) .
Subfascial muscular tissue in the multifidus muscle was estimated by manual tracing at the same level on preoperative plain CT images and the mean CT values [Hounsfield units (HU)] for these areas were determined using the Aquarius NET server (Tera Recon, Inc., San Mateo, CA, USA). We placed 4 circles on areas of subcutaneous fat away from major vessels in CT images, which were used as the region of interest (ROI) of subcutaneous fat. The mean CT values (HU) for the ROI of subcutaneous fat were also measured. IMAC was calculated by the ratio of these CT values, as previously reported by Kitajima, as follows. 12, 13 IMAC = mean CT value of ROI of multifidus muscle (HU) / mean CT value of ROI of subcutaneous fat (HU).
High IMAC was regarded as a proxy for low muscle quality (Fig 1B) .
Cut-off values for PMI and IMAC
Because the range of PMI in males and females is quite different, we established different cut-off lines for each using receiver operating characteristic (ROC) curves. The cut-off values were selected on the basis of best accuracy in relation to an outcome (death Based on these cut-off values, patients were assigned to 1 of 2 groups, low PMI (n = 64) and normal/high PMI (n = 166). The cut-off values for IMAC in males and females were -0.343 (AUC = 0.626) and -0.256 (AUC = 0.610), respectively. Based on these cut-off values, patients were assigned to 1 of 2 groups, high IMAC (n = 142) and normal/low IMAC (n = 88). Patient-related factors, tumor-related factors, surgical variables, postoperative complications, and rate of completion of chemotherapy were compared according to PMI and IMAC.
Analyzed parameters
The OS and RFS rates after pancreatic resection were investigated in patients classified as PMI or IMAC. Prognostic factors were examined with respect to those rates using the following variables:
skeletal muscle mass (low PMI vs. normal/high PMI), skeletal muscle quality (high IMAC vs. and adjuvant chemotherapy (presence vs. absence). Modified GPS was calculated as previously described. 14 Briefly, patients with both elevated CRP (> 1.0 mg/dl) and hypoalbuminemia (< 3.5 g/dl)
were given a score of 2, patients with elevated CRP and without hypoalbuminemia a score of 1, and those with normal CRP a score of 0. PNI was calculated as 10×albumin (g/dl)+0.005×total lymphocyte count(/μl). 15 Postoperative complications were classified according to Clavien-Dindo classification, 16 with complications classified as grade 3 or greater considered to indicate the presence of postoperative complications. Adjuvant chemotherapy was performed with gemcitabine, S-1, or both, with a duration over 6 months considered as the presence of adjuvant chemotherapy. Resection curability was classified as R1 (complete resection with no grossly visible tumor as defined by the surgeon, but margins microscopically positive according to pathologist) and R0 (complete resection with no microscopic residual tumor). All of these parameters could be retrospectively extracted from patient's clinical records.
Statistical analysis
Data are presented as the mean ± standard deviation (SD) for continuous variables. Continuous variables were non-parametrically analyzed using a Mann-Whitney U test. Categorical variables were compared using a χ² test or Fisher's exact test as appropriate. Any variable with P < .10 in univariate analysis using the above tests was considered to be a candidate for multivariate analysis using the Cox proportional hazard model. Cumulative OS and RFS rates were calculated using the Kaplan-Meier method, and differences between curves were evaluated using a log-rank test. A P value < .05 was considered to indicate significance. All statistical data were generated using JMP 11 (SAS Institute, Cary, NC, USA) and Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). (Fig 2A) , while IMAC in males (-0.333, -0.777 to +0.077) was significantly lower than that in females (-0.182, -0.469 to +0.284) (P < .001) (Fig 2B) . PMI was significantly inversely correlated with age in males (P = .002, r = -0.280), while there was no correlation in females (P = .513, r = 0.065) (Fig 2C) , and IMAC was positively correlated with age in both males (P < .001, r = 0.490) and females (P < .001, r = 0.348) (Fig 2D) . There was no significant correlation observed between PMI and IMAC (males P = .372, r = -0.081; females P = .277, r = 0.107).
Results
Correlations of PMI and IMAC with patient age
Baseline characteristics of patients classified according to PMI
Clinicopathological characteristics of patients with low and normal/high PMI are shown in Table I .
Patients with low PMI were significantly older than those with normal/high PMI (P = .002), while their body mass index (BMI) was significantly lower (P < .001). There were no significant differences between the low and normal/high PMI groups in regard to other patient-related factors, tumor-related factors, surgical variables, postoperative complications, and preoperative neo-adjuvant chemotherapy.
However, the completion rate of postoperative adjuvant chemotherapy was significantly lower in patients with low PMI (65.6% vs. 80.1%, P = .021). The reasons of the cessation of chemotherapy in patients with low PMI were patient's poor general conditions (n=10; 45.5%), adverse effects of chemotherapy (n=2; 9.1%), and patient's advanced age (n=2; 9.1%).
Baseline characteristics of patients classified according to IMAC
Clinicopathological characteristics of patients with high and normal/low IMAC are shown in Table   II . Patients with high IMAC were significantly older than those with normal/low IMAC (P = .001), while their BMI was significantly higher (P = .007). There were no significant differences between the high and normal/low IMAC groups in regard to the other factors except for tumor size. Furthermore, the completion rate of postoperative adjuvant chemotherapy was significantly lower in patients with high IMAC (69.0% vs. 87.5%, P = .001). The reasons of the cessation of chemotherapy in patients with high were no significant differences for causes of death between the 2 subgroups (P = .448). Similarly, between the 2 subgroups classified according to IMAC, we found no significant differences in regard to causes of death (P = .214).
Risk factors for poor outcome in patients undergoing pancreatic resection
In univariate analysis, low PMI (lower skeletal muscle mass), high IMAC (lower skeletal muscle quality), lower PNI, higher CA19-9 level, tumor size, lymphatic vessel invasion, perineural invasion, nodal metastasis, R1 resection, and absence of adjuvant chemotherapy were identified as significant risk factors for death after pancreatic resection for pancreatic cancer. Multivariate analysis identified low PMI, high IMAC, male gender, poorly differentiated tumor, lymphatic vessel invasion, nodal metastasis, R1
resection, and absence of adjuvant chemotherapy as 8 independent significant risk factors for death after pancreatic resection for pancreatic cancer (Table III) .
Univariate analysis also revealed that low PMI, high IMAC, lower PNI, higher CA19-9 level, tumor size, lymphatic vessel invasion, perineural invasion, nodal metastasis, and R1 resection were significant risk factors for pancreatic cancer recurrence after the operation. Multivariate analysis identified low PMI, high IMAC, nodal metastasis, and R1 resection as 4 independent risk factors for pancreatic cancer recurrence after the operation (Table IV) .
Thus, lower skeletal muscle mass and lower skeletal muscle quality were both identified as independent risk factors for OS and RFS.
Discussion
The results of our retrospective study revealed that preoperative PMI and IMAC are independent risk factors for mortality after curative resection of pancreatic cancer. The previous report regarding the relationship between sarcopenia and pancreatic cancer focused only on skeletal muscle mass 8 . To the best of our knowledge, this is the first study to investigate the impact of skeletal muscle quality on survival after pancreatic cancer resection.
In previous reports, only skeletal muscle mass was used to define sarcopenia, because muscle strength and function are difficult to evaluate. Indeed, it is considered that muscle mass and strength are highly correlated, and that loss of muscle strength is a direct result of lost muscle mass. However, some patients may have lower levels of muscle function and strength even though muscle mass seems to be adequate, because of reduced muscle quality. High IMAC indicates a lower level of lean muscle mass as well as higher level of intramuscular adipose tissue. Therefore, we used intramuscular adipose tissue accumulation with PMI to evaluate preoperative sarcopenia. Several studies have shown that loss of muscle tissue in sarcopenia is accompanied by infiltration with fat and connective tissue, a condition known as myosteatosis. 17 Assessments of skeletal muscle quality and intramuscular fat infiltration are therefore crucial for considering sarcopenia.
In our study, though patients with normal-high PMI were considered to have normal muscle volume, patients with low muscle quality in this group had a high risk for poor survival. The OS and RFS rates for patients with normal-high PMI/ high IMAC were significantly lower than those for patients with normal-high PMI/ normal-low IMAC (P < .001, P = .046, respectively), which indicates that patient prognosis is highly dependent on the quality of skeletal muscle and those with low muscle quality have a poor prognosis even if muscle volume is near normal. Thus, assessment of only muscle volume is not sufficient, and evaluations of both quality and quantity of skeletal muscle are more reliable for predicting prognosis.
Following resection of pancreatic cancer, prognosis was shown to depend on several tumor-specific factors including tumor size, tumor differentiation, lymph node metastasis, and resection margin status.
However, prognosis after surgery is multifactorial, and related to not only tumor-specific factors but also individual patient characteristics. Moreover, most tumor-specific factors can only be determined after shown to be released from skeletal muscle, and several adipocytokines (called adipokines), such as adiponectin and leptin, released from adipose tissue. 25 Myokines are considered to balance and counteract the effects of adipokines. Furthermore, the associations among immunity, inflammation, and adipocytokines have recently been emphasized as key mechanisms by which sarcopenia affects patient survival. 17, 26 We are currently implementing preoperative and postoperative nutritional and exercise therapeutic protocols, especially for patients with sarcopenia or with poor nutritional status. Although the ideal period of these perioperative therapy before and after operation is not established, in our opinion, at least one month before operation and a few months after operation are required to improve sarcopenia.
However, the duration of preoperative intervention should be decided incorporating the progression of pancreatic cancer during such intervention. Our group previously reported the impact of nutritional therapy on prognosis after living-donor liver transplantation, especially in patients with sarcopenia.
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trust that our supportive therapy will also improve the prognosis of pancreatic cancer patients, though whether nutritional and exercise therapy is truly effective must be clarified in a prospective study.
Preoperative PMI and IMAC can be very reliable parameters for prognosis after surgery. In addition, risk stratification for sarcopenia can be easily performed before surgery using these parameters. Such risk stratification and scoring would be useful for making clinical decisions, and also when considering indication of surgery for high-risk patients, though further investigations are needed. At present, we would rather make supportive interventions for high-risk patients than change our surgical indication for potentially resectable pancreatic cancer.
There are several limitations to our study. First, the correlation of IMAC and skeletal muscle strength could not be investigated because of the retrospective study design. However, recent investigations have shown that intramuscular fat accumulation contributes to declines in muscle strength and quality.
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Higher attenuation value, or density, of skeletal muscle shown by CT was reported to be associated with greater muscle strength independent of muscle volume. 28 These findings support our notion that IMAC is a possible new parameter to assess sarcopenia instead of solely measuring muscle strength. In addition,
for evaluation of sarcopenia, we are now conducting a prospective study to examine other parameters of muscle function, such as grip strength, walking speed, and levels of exhaustion, in which we hope to reveal the relationship between IMAC and muscle strength. Because of the retrospective study design, we couldn't investigate the extent of preoperative body weight loss from patient charts. We would like to prospectively investigate the relationship between preoperative body weight loss and sarcopenia markers. As for measurements using CT images, we chose to utilize the psoas muscle as a means to evaluate skeletal muscle mass and the multifidus muscle to evaluate skeletal muscle quality at the umbilical level in cross-sectional CT images, as previously reported; however, other approaches have been advocated (e.g., total skeletal muscle mass at L3 level). 4 ,29 Another point we have to keep in mind is that the completion rate of adjuvant chemotherapy in patients with low PMI was significantly lower than that of those with normal/high PMI (65.6% vs. 80.1%), and the rate in patients with high IMAC was significantly lower than that in those with normal/low IMAC (69.0% vs. 87.5%), which might have influenced patient survival to some extent. In patients with sarcopenia and advanced age, we are often obliged to abandon chemotherapy because of their poor general condition and severe adverse effects.
However, in multivariate analysis, low PMI and high IMAC remained as independent prognostic factors for poor survival even after adjustment for the influence of chemotherapy. Finally, it is important to consider whether our cut-off values for PMI and IMAC are adequate to define sarcopenia. Several previous reports utilized separate definitions for sarcopenia, though there remains no consensus or objective criteria to define the condition. In the present study, we determined cut-off values for PMI and IMAC based on ROC curves, which is considered to be a more accurate and objective method than use of SD for setting cut-off values. However, further investigations are necessary.
In conclusion, preoperative sarcopenia, defined by both quality and quantity of skeletal muscle, was 
